


Amplification-free sensing of
circulating nucleic acid biomarkers in
blood:

**A minimally invasive tool for early
diagnosis of cancer**

Molecular Bioengineering

*How an academically
trained chemist (or
molecular bioengineer)*



*working in a Bioengineering
department*

*can address public health problems and
engineer solutions for cancer*

Our goal: Diagnose more cancers better and earlier

Increasing survival rate by treating early, only if necessary and with the best suited drugs requires...

- ★ **Highly specific biomarkers** (or combination of biomarkers)
- ★ **Non-invasive tests** for widespread public screening (affordable, robust and easy-to-use)

Prostate cancer: A case study

Prostate cancer is currently diagnosed too late

In the UK only, around 35,000 new cases diagnosed per year, around a quarter would be already metastatic - but that's only in the UK

And non-invasive diagnostic blood tests lack specificity

Current diagnosis results from the presentation of clinical symptoms such as urine hesitancy, erectile dysfunction and decreased urination flow, whereupon a plasma or serum sample's prostate specific antigen (PSA) concentration will be assessed. Typically, results of 4ng/ml or above result in a prostate biopsy to confirm a neoplasm. However, it is reported that over **75% of positive PSA tests are in fact false positives**

Public screening

from NHS website

"There is currently no screening programme for prostate cancer in the UK [...] Instead of a national screening programme, there is an informed choice programme on prostate cancer risk management. It aims to give men good information on the pros and cons of a PSA test"





Private healthcare offers patients a prostate cancer screening service.

ProstateCheck: £360

Follow-up appointments range from £200 to £250

Could eliminate 30-50% of all unnecessary biopsies

Our answers to an unsolved problem



- Minimal sample volume
- Automated sample processing
- Benchtop analysis
- High specificity
- Low cost

Our Target: Circulating micro RNAs

Need for reliable, highly sensitive, specific and quantitative sensing technology


- Secretion in body fluids (saliva, serum, plasma...)

Ideal for minimally invasive diagnosis


BUT

- Low concentration in these cell-free fluids
- miRNAs have very similar sequences


The gold standard: RT-qPCR and Taqman probes



- Taqman probes **expensive** and often unreliable (**lack of specificity**, reproducibility and **strong background** fluorescence)
- Double amplification (prone to **contamination** and source of **errors**)




Our Strategy: Oligonucleotide-templated reactions




Using a DNA or RNA strand as a template to catalyse an otherwise unfavourable reaction of formation of a fluorescent dye

Our scaffold: Peptide Nucleic Acids (PNAs)





Our probe-heads: A toolbox of multicolour dyes



Emission λ_{max} = 520-530 nm
Coumarin unquenching

Emission λ_{max} = 550-555 nm
Cy3 synthesis

Possibility of multiplexed (multicolour) analysis

Emission λ_{max} = 600-605 nm
C3 synthesis

Emission λ_{max} = 645-650 nm
Squaraine dye synthesis


M. Sleiman, S. Ladame, *Chem. Commun.* **2014**, 50, 5288.

K. Meguellati, G. Koripelly, S. Ladame, *Angew. Chem. Int. Ed.* **2010**, 49, 2738.


G. Koripelly, K. Meguellati, S. Ladame, *Bioconjug. Chem.* **2010**, 21, 2103.

Our Chemistry: Reaction of fluorescence unquenching

*Quenched fluorescence
(by PET)*



Strong Fluorescence




Emission $\lambda_{\text{max}} = 520\text{-}530 \text{ nm}$



Proof-of-concept study





MiR-141 and miR-375: biomarkers for prostate cancer (high levels compared to healthy controls)

MiR-132: biomarker for ovarian cancer (low levels compared to healthy controls)



miR-141

In vitro validation





Quantitative detection
Relatively fast

Specific detection



Sequence specificity



Specificity at the single nucleotide level
(but position-dependent)

Implications for miR141 and miR375 sensing?




Sequence specificity

miR375: No other miR with sequence homology >75%

miR141: 90.90% homology (20/22bp) with miR-200a

miR-141 sequence (5' to 3'): UAA CAC UGU CUG GUA AAG AUG G
miR-200a sequence (5' to 3'): UAA CAC UGU CUG GUA ACG AUG U



Likely to detect both
miR141 and miR200a
simultaneously



The issue of Sensitivity

LITTLE and CONCENTRATION
endogenous molecules

highly dependent on
how the sample has
been processed

PRACTICAL

Is our technology

Picomolar?
Femtomolar?
Attomolar?

information on
conditions available

the sample has
been analysed

TECHNIQUE

PURPOSE?

Human
serum

To
extract

RNA
extraction


PNA probes

RT-qPCR





RN: Remission, post-prostate removal
RY: Remission, prostate gland present
AL: Localised advanced tumour
AM: Metastatic advanced tumour

Validation on Pca samples




Technology
fit-for-purpose

Amplification-free
Detection




Good correlation with
RT-qPCR data

PCa diagnosis and grading





Cross-validation: ovarian vs prostate cancer





- Can detect both increasing and decreasing levels of miRNAs
- miR141 behaves as reference miRNA for ovarian Cancer




Mature *VS* pre-miR

Why no amplification required?



PNA probes can detect mature miRNAs but also their precursors


By-passing sample processing?





By-passing sample processing?

Can we avoid RNA extraction?



Vision for the future

- A technology of **broad applicability**, also to **cancers with low survival rates** (lung, pancreatic, oesophageal)
- A **versatile** technology suitable for the detection of **any circulating nucleic acid biomarkers** (combining miRNA, cell-free DNA and SNP detection in one device for improved specificity).
 - *Minimally invasive* (simple blood test)
 - *Highly automated* (minimal sample processing)
 - *Low production cost* (probes costing <1p per test)
 - *Amenable to incorporation in portable devices* (isothermal, no enzyme, fast)

Acknowledgements

Mr Gavin Metcalf (Poster 029)
Miss Dana Al Sulaiman (Poster 002)
Mr Hinesh Patel
Mr Akifumi Shibakawa
Miss Isobel Steer
Miss Roberta Menezes (Poster 013)
Dr Jean-Francois Bartolo
Dr Mazen Sleiman

Collaborators:

Prof. Charlotte Bevan (ICL)
Prof. Bob Brown (ICL)
Prof. Charles Coombes (ICL)
Prof. Valerie Taly (France)



Engineering and Physical Sciences
Research Council